Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McKesson, Priority And Besse Will Distribute Pfizer/Eyetech's Macugen

This article was originally published in The Pink Sheet Daily

Executive Summary

McKesson, Priority and Besse will be specialty distributors for Pfizer/Eyetech's wet age-related macular degeneration treatment Macugen (pegaptanib)

You may also be interested in...



Macugen Access Program Will Help Seniors With Medicare Copay

MAP is designed to assure access to the ophthalmic agent for seniors who "may have difficulty paying the 20% copay," Eyetech COO says. Macugen carries an average wholesale price of $1,243 per injection.

Macugen Access Program Will Help Seniors With Medicare Copay

MAP is designed to assure access to the ophthalmic agent for seniors who "may have difficulty paying the 20% copay," Eyetech COO says. Macugen carries an average wholesale price of $1,243 per injection.

Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label

The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel